CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural...

Genomics Market is anticipated to reach US$ 49,996.15 Mn by 2027

Genomics Market is anticipated to...

Bionano Genomics Symposium to feature OGM Presentations and Live Panel Discussion

Bionano Genomics Symposium to feature...

What is the Importance of Gene Editing in Farming?

What is the Importance of Gene...

Autolomous and Vineti to Establish a Fully Integrated End-To-End CGT Delivery Pathway Together

Autolomous and Vineti to Establish a...

Genome Editing: What Makes CRISPR-Cas9 a Preferred Choice?

Genome Editing: What Makes...

4 Diseases That Could Be Cured Using CRISPR Technology

4 Diseases That Could Be Cured Using...

Genome Editing Market: Development, Prospective and Regional Vision

Genome Editing Market: Development,...

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural...

Genomics Market is anticipated to reach US$ 49,996.15 Mn by 2027

Genomics Market is anticipated to...

Bionano Genomics Symposium to feature OGM Presentations and Live Panel Discussion

Bionano Genomics Symposium to feature...

What is the Importance of Gene Editing in Farming?

What is the Importance of Gene...

Autolomous and Vineti to Establish a Fully Integrated End-To-End CGT Delivery Pathway Together

Autolomous and Vineti to Establish a...

Genome Editing: What Makes CRISPR-Cas9 a Preferred Choice?

Genome Editing: What Makes...

4 Diseases That Could Be Cured Using CRISPR Technology

4 Diseases That Could Be Cured Using...

Genome Editing Market: Development, Prospective and Regional Vision

Genome Editing Market: Development,...

BlueAllele Corporation Acquires a Patent for Cutting-Edge Gene Editing Technology

Life Sciences Review Life Sciences Review | Monday, September 06, 2021
Tweet

BlueAllele Corporation is the recipient of a patent for advanced gene-editing technology.


Fremont, CA: The United States Patent and Trademark Office has granted United States Patent No. 11,091,756 (the 756 Patent) to BlueAllele Corporation for the use of BlueAllele's PALIDON™ technology.


BlueAlleles PALIDON repair templates have a palindromic, bidirectional structure optimized to take advantage of the high rate of non-homologous end joining (NHEJ) repair found in cells while retaining the capacity to correct damaged mRNA and protein precisely. Due to the compatibility of PALIDON repair templates with existing gene-editing nucleases and delivery systems, PALIDON is particularly well suited for targeting a wide variety of loss-of-function and gain-of-function monogenic disorders.


PALIDON's palindromic design transforms a previously unintended consequence (reverse integration) into a functional event that increases efficacy. By incorporating PALIDON into introns, any potential error induced by the NHEJ pathway can be tolerated, resulting in a reduction in undesirable byproducts. PALIDON captures the endogenous gene's natural expression, allowing for unprecedented control of protein levels and stable, long-lasting modifications.


“We are pleased that the USPTO has recognized the significance of our PALIDON technology and granted 


this patent. Protecting intellectual property is a critical part of our business model, particularly as we continue to develop novel and innovative methods for achieving precise gene correction,” said Dr. Nicholas J. Baltes, BlueAlleles chief scientific officer. “Further, the grant of this new patent highlights the unmet need for improving the precision, efficacy and versatility of insertion-based gene editing approaches. As the examiner of the 756 Patent noted, PALIDON expands the field of CRISPR technology in a novel way that was not recognized by prior researchers in this area.”


The 756 Patent comprises claims relating to methods for editing genes with PALIDON. Additionally, the issued claims cover PALIDON's usage in any cell type or system (e.g., animal cells for in vitro or in vivo applications), as well as its use to fix any gene in the genome, offering broad coverage for its use in human therapies.


“This patent demonstrates our expertise and commitment to unlocking the full potential of gene editing for treating genetic diseases,” said Joseph B. Saluri, BlueAlleles chief executive officer. “We are excited to continue advancing our PALIDON platform, along with the other innovative gene correction technologies in our R&D pipeline.”


BlueAllele Corporation is the only owner of the 756 Patent.


Weekly Brief

loading
> <
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue

Read Also

Role of Predictive Genomics in Sustainable Healthcare

Role of Predictive Genomics in Sustainable Healthcare

A Conversational AI Approach to Regulatory Intelligence

A Conversational AI Approach to Regulatory Intelligence

A rise in DNA Sequencing Market is expected in coming years

A rise in DNA Sequencing Market is expected in coming years

Omniabio Inc. Announces Private Investor

Omniabio Inc. Announces Private Investor
Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Lithuania's Vision to Become a Biotech Hub in Europe

Lithuania's Vision to Become a Biotech Hub in Europe

Bridging the Diversity Gap in Genomics

Bridging the Diversity Gap in Genomics

How does Biotechnology Provide Solutions to Human Needs?

How does Biotechnology Provide Solutions to Human Needs?
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/blueallele-corporation-acquires-a-patent-for-cuttingedge-gene-editing-technology-nwid-541.html